Zeiss is launching MyoCare, its first age-specific myopia management portfolio with lens designs aimed at slowing myopia progression.

The design of Zeiss MyoCare uses microstructures called CARE (cylindrical annular refractive elements) to induce simultaneous competing myopic defocus on the peripheral retina to slow down myopia progression, explained said Elmarie Pretorius, professional services manager for Zeiss Vision Care ANZ. “The CARE technology incorporates alternating defocus and correction zones expanding towards the periphery of the lens. Due to the eyes moving behind the spectacle lens and with a focus on optimal wearability and efficacy, an optimised freeform back surface is provided to minimise hyperopic defocus.”

Supported by interim results from a two-year clinical trial led by Wenzhou Medical University Eye Hospital in China, (including 78 myopic children wearing Zeiss MyoCare Rx lenses, 72 myopic children wearing MyoCare S Rx lenses and 76 myopic children wearing Zeiss single-vision lenses), Zeiss is launching two design variants of the lens. The MyoCare lens is recommended for children younger than 10 years, while MyoCare S is for older children. Using emmetropic progression ratio as a measure of effectivity, the trial found the designs demonstrated an average emmetropic progression ratio for axial length of up to 86% for children aged 10-12 years and 63% for children aged 7-9 years. Of the children who participated in the study, 98% claimed their distance and near vision was very good when wearing the MyoCare designs. They all adapted to the lenses within one day.

The Zeiss MyoCare portfolio delivers full UV protection and will be available in a wide range of materials and indices, said the company.